NPPA Fixes Retail Prices of 37 Drug Formulations Including Atorvastatin, Ezetimibe, Telmisartan, Details We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok Source link
Eli Lilly, Novo Nordisk race to lock in India obesity drug market We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok Source link
Obesity drugs are rapidly moving from the margins of lifestyle care to the centre of India’s pharmaceutical growth story as rising lifestyle diseases, new blockbuster launches and the looming entry of low-cost generics reshape the market. With global consultants McKinsey ranking obesity therapies alongside AI, electric vehicles and robotics as trillion-dollar opportunities by 2040, India…
State Drug Alert: 141 Medicine Samples Including Mankind’s Telmisartan Fail CDSCO Quality Tests in November We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok Source link
New Delhi, Drug firm Cipla on Monday said it has launched orally inhaled insulin powder for diabetes patients in the country. The company had obtained regulatory approval from the Central Drugs Standard Control Organisation (CDSCO) late last year for the exclusive distribution and marketing of Afrezza, a rapid-acting orally inhaled insulin, which offers a needle-free,…
Cipla Secures Exclusive Rights to Sell Corex, Dolonex, Neksium, Dalacin C Under Pfizer Deal We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok Source link
Pharmaceutical companies Pfizer India and Cipla Limited today announced a partnership where Cipla will exclusively market and distribute four key brands of Pfizer in India. Under the agreement, Cipla now has the sole right to market, distribute and sell the cough syrup- Corex Dx and Corex LS, the non-steroidal anti-inflammatory drug (NSAID) Dolonex, the proton…
Drugmaker Cipla on Wednesday said it has launched a medication for managing obesity and type-2 diabetes mellitus. The company has launched Yurpeak (tirzepatide), a one-weekly injectable therapy for obesity and type-2 diabetes mellitus, two of the country’s most pressing health challenges, the Mumbai-based drugmaker said in a regulatory filing. The company has the rights to…
Indian Pharma Market Posts 9% Surge in November Even as Volumes Stay Flat: PharmaTrac We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok Source link
Danish drugmaker Novo Nordisk will launch its blockbuster diabetes drug Ozempic in India this month, three sources familiar with the matter said, as it seeks to strengthen its foothold in the world’s most populous nation. India has the second-highest number of people with type 2 diabetes after China and rising obesity rates, making it a…